- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00153088
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy
A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study -
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective, randomised, double-blind, multicentric and comparative study to investigate, on a long-term basis, the preventive effect on the transition to overt nephropathy and the safety of Telmisartan (Micardis) against placebo in patients with diabetic nephropathy, manifesting microalbuminuria associated with type II diabetes.
Study Hypothesis:
The hypothesis is that Telmisartan (Micardis) at 40 mg or 80 mg versus placebo control in patients with concurrent type II diabetic mellitus or diabetic nephropathy demonstrating microalbuminuria, has the preventive effect on transition from incipient to overt nephropathy.
Comparison(s):
The primary endpoint is defined as the transition from incipient to overt nephropathy, and the non-transition curve will be demonstrated based on the Kaplan-Meier method. The evaluation criteria for the point to transition to overt nephropathy is defined as urinary albumin to creatinine ratios at consecutive 2 measuring points increasing over 300 mg/g-Creatinine and excess 30% increase comparing with the baseline value. The curve of non-transition will be compared with Logrank test. Those in BIBR277 groups are sequentially compared with that in the placebo group by the closed testing procedure.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Adachi-ku, Tokyo, Japan, 121-0813
- Boehringer Ingelheim Investigational Site
-
Amagasaki, Hyogo, Japan, 661-0002
- Boehringer Ingelheim Investigational Site
-
Arakawa-ku, Tokyo, Japan, 116-0011
- Boehringer Ingelheim Investigational Site
-
Asaguchi-gun, Okayama, Japan, 719-0113
- Boehringer Ingelheim Investigational Site
-
Asahi, Chiba, Japan, 289-2511
- Boehringer Ingelheim Investigational Site
-
Asahikawa, Hokkaido, Japan, 070-8610
- Boehringer Ingelheim Investigational Site
-
Asahikwa, Hokkaido, Japan, 070-8530
- Boehringer Ingelheim Investigational Site
-
Atami, Shizuoka, Japan, 413-0012
- Boehringer Ingelheim Investigational Site
-
Atsugi,Kanagawa, Japan, 243-0013
- Boehringer Ingelheim Investigational Site
-
Chikugo, Fukuoka, Japan, 833-0041
- Boehringer Ingelheim Investigational Site
-
Chisagata-gun, Nagano, Japan, 386-0396
- Boehringer Ingelheim Investigational Site
-
Chisagata-gun, Nagano, Japan, 386-0493
- Boehringer Ingelheim Investigational Site
-
Chitose, Hokkaido, Japan, 066-0081
- Boehringer Ingelheim Investigational Site
-
Chiyoda, Tokyo, Japan, 100-0005
- Boehringer Ingelheim Investigational Site
-
Chiyoda-ku, Tokyo, Japan, 101-8326
- Boehringer Ingelheim Investigational Site
-
Chiyoda-ku, Tokyo, Japan, 102-8798
- Boehringer Ingelheim Investigational Site
-
Ebina, Kanagawa, Japan, 243-0432
- Boehringer Ingelheim Investigational Site
-
Fujisawa, Kanagawa, Japan, 252-0802
- Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japan, 814-0163
- Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japan, 812-0053
- Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japan, 814-0171
- Boehringer Ingelheim Investigational Site
-
Fukuyama, Hiroshima, Japan, 720-0825
- Boehringer Ingelheim Investigational Site
-
Funabashi, Chiba, Japan, 247-0805
- Boehringer Ingelheim Investigational Site
-
Furukawa, Miyagi, Japan, 989-6183
- Boehringer Ingelheim Investigational Site
-
Gifu, Gifu, Japan, 501-1198
- Boehringer Ingelheim Investigational Site
-
Gobo, Wakayama, Japan, 644-0011
- Boehringer Ingelheim Investigational Site
-
Hachioji, Tokyo, Japan, 193-0998
- Boehringer Ingelheim Investigational Site
-
Hakodate, Hokkaido, Japan, 040-8585
- Boehringer Ingelheim Investigational Site
-
Hanamaki, Iwate, Japan, 025-0075
- Boehringer Ingelheim Investigational Site
-
Hannan, Osaka, Japan, 599-0202
- Boehringer Ingelheim Investigational Site
-
Hashima-gun, Gifu, Japan, 501-6062
- Boehringer Ingelheim Investigational Site
-
Hatsukaichi, Hiroshima, Japan, 738-0033
- Boehringer Ingelheim Investigational Site
-
Hirakata, Osaka, Japan, 573-1196
- Boehringer Ingelheim Investigational Site
-
Hitachiota, Ibaragi, Japan, 313-0014
- Boehringer Ingelheim Investigational Site
-
Ichinomiya, Aichi, Japan, 491-8551
- Boehringer Ingelheim Investigational Site
-
Iida, Nagano, Japan, 395-8558
- Boehringer Ingelheim Investigational Site
-
Ikeda, Osaka, Japan, 563-8510
- Boehringer Ingelheim Investigational Site
-
Inashiki-gun, Ibaragi, Japan, 300-0395
- Boehringer Ingelheim Investigational Site
-
Isehara, Kanagawa, Japan, 259-1193
- Boehringer Ingelheim Investigational Site
-
Isezaki, Gunma, Japan, 372-0001
- Boehringer Ingelheim Investigational Site
-
Itami, Hyogo, Japan, 664-8533
- Boehringer Ingelheim Investigational Site
-
Izumisano, Osaka, Japan, 598-0048
- Boehringer Ingelheim Investigational Site
-
Kamakura, Kanagawa, Japan, 247-0055
- Boehringer Ingelheim Investigational Site
-
Kamakura, Kanagawa, Japan, 247-0056
- Boehringer Ingelheim Investigational Site
-
Kamogawa, Chiba, Japan, 296-8602
- Boehringer Ingelheim Investigational Site
-
Katsushika-ku, Tokyo, Japan, 125-0041
- Boehringer Ingelheim Investigational Site
-
Kawagoe, Saitama, Japan, 350-0042
- Boehringer Ingelheim Investigational Site
-
Kawaguchi, Saitama, Japan, 332-8558
- Boehringer Ingelheim Investigational Site
-
Kawasaki, Kanagawa, Japan, 210-0013
- Boehringer Ingelheim Investigational Site
-
Kawasaki, Kanagawa, Japan, 210-0924
- Boehringer Ingelheim Investigational Site
-
Kawasaki, Kanagawa, Japan, 211-0035
- Boehringer Ingelheim Investigational Site
-
Kawasaki, Kanagawa, Japan, 211-8510
- Boehringer Ingelheim Investigational Site
-
Kawasaki, Kanagawa, Japan, 215-0022
- Boehringer Ingelheim Investigational Site
-
Kawasaki, Kanagawa, Japan, 216-8511
- Boehringer Ingelheim Investigational Site
-
Kisarazu, Chiba, Japan, 292-8535
- Boehringer Ingelheim Investigational Site
-
Kita-katushika-gun, Saitama, Japan, 349-1105
- Boehringer Ingelheim Investigational Site
-
Kita-ku, Tokyo, Japan, 114-0004
- Boehringer Ingelheim Investigational Site
-
Kitami, Hokkaido, Japan, 090-0040
- Boehringer Ingelheim Investigational Site
-
Kobe, Hyogo, Japan, 651-1242
- Boehringer Ingelheim Investigational Site
-
Kobe, Hyogo, Japan, 654-0047
- Boehringer Ingelheim Investigational Site
-
Kochi, Kochi, Japan, 780-8562
- Boehringer Ingelheim Investigational Site
-
Kochi, Kochi, Japan, 781-0011
- Boehringer Ingelheim Investigational Site
-
Kodaira, Tokyo, Japan, 187-0003
- Boehringer Ingelheim Investigational Site
-
Kodaira, Tokyo, Japan, 187-8510
- Boehringer Ingelheim Investigational Site
-
Komaki, Aichi, Japan, 485-8520
- Boehringer Ingelheim Investigational Site
-
Komatsushima, Tokushima, Japan, 773-8502
- Boehringer Ingelheim Investigational Site
-
Koriyama, Fukushima, Japan, 963-8563
- Boehringer Ingelheim Investigational Site
-
Koriyama, Fukushima, Japan, 963-8585
- Boehringer Ingelheim Investigational Site
-
Koriyama,Fukushima, Japan, 963-8022
- Boehringer Ingelheim Investigational Site
-
Kounan, Aichi, Japan, 483-8702
- Boehringer Ingelheim Investigational Site
-
Kumagaya, Saitama, Japan, 360-0854
- Boehringer Ingelheim Investigational Site
-
Kurashiki, Okayama, Japan, 701-0192
- Boehringer Ingelheim Investigational Site
-
Kurashiki, Okayama, Japan, 710-0826
- Boehringer Ingelheim Investigational Site
-
Kyoto, Kyoto, Japan, 615-8087
- Boehringer Ingelheim Investigational Site
-
Matsuyama, Ehime, Japan, 790-0024
- Boehringer Ingelheim Investigational Site
-
Matsuyama, Ehime, Japan, 791-8026
- Boehringer Ingelheim Investigational Site
-
Minato-ku, Tokyo, Japan, 106-0045
- Boehringer Ingelheim Investigational Site
-
Minato-ku, Tokyo, Japan, 108-0073
- Boehringer Ingelheim Investigational Site
-
Minato-ku, Tokyo, Japan, 192-0363
- Boehringer Ingelheim Investigational Site
-
Musashino, Tokyo, Japan, 180-8610
- Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan, 451-8511
- Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan, 454-0933
- Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan, 455-8530
- Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan, 462-0802
- Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan, 462-0825
- Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan, 465-0025
- Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japan, 467-8602
- Boehringer Ingelheim Investigational Site
-
Nakano-ku, Tokyo, Japan, 164-0011
- Boehringer Ingelheim Investigational Site
-
Nangoku, Kochi, Japan, 783-8505
- Boehringer Ingelheim Investigational Site
-
Nishinomiya, Hyogo, Japan, 662-0971
- Boehringer Ingelheim Investigational Site
-
Nishinomiya, Hyogo, Japan, 663-8211
- Boehringer Ingelheim Investigational Site
-
Nishinomiya, Hyogo, Japan, 663-8501
- Boehringer Ingelheim Investigational Site
-
Noda, Chiba, Japan, 278-8501
- Boehringer Ingelheim Investigational Site
-
Nomi, Ishikawa, Japan, 923-1226
- Boehringer Ingelheim Investigational Site
-
Obihiro, Hokkaido, Japan, 080-0848
- Boehringer Ingelheim Investigational Site
-
Odawara, Kanagawa, Japan, 250-0011
- Boehringer Ingelheim Investigational Site
-
Oita, Oita, Japan, 870-0039
- Boehringer Ingelheim Investigational Site
-
Okawa, Fukuoka, Japan, 831-0016
- Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japan, 700-8505
- Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japan, 700-8558
- Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japan, 701-1192
- Boehringer Ingelheim Investigational Site
-
Osaka, Japan, 545-0021
- Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japan, 543-0002
- Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japan, 543-0035
- Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japan, 553-0003
- Boehringer Ingelheim Investigational Site
-
Osaka-sayama, Osaka, Japan, 589-8511
- Boehringer Ingelheim Investigational Site
-
Otaru, Hokkaido, Japan, 047-8550
- Boehringer Ingelheim Investigational Site
-
Oyama, Tochigi, Japan, 323-0022
- Boehringer Ingelheim Investigational Site
-
Sagamihara, Kanagawa, Japan, 228-8555
- Boehringer Ingelheim Investigational Site
-
Sagamihara, Kanagawa, Japan, 229-1125
- Boehringer Ingelheim Investigational Site
-
Sakai, Osaka, Japan, 590-0132
- Boehringer Ingelheim Investigational Site
-
Sakai, Osaka, Japan, 591-8025
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 001-0023
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 001-0024
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 003-0023
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 003-8585
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 004-0053
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 006-0811
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 060-0033
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 060-0062
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 062-0007
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 062-0931
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 064-0953
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 064-8622
- Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japan, 065-0027
- Boehringer Ingelheim Investigational Site
-
Sendai, Miyagi, Japan, 980-0021
- Boehringer Ingelheim Investigational Site
-
Sendai, Miyagi, Japan, 981-8501
- Boehringer Ingelheim Investigational Site
-
Setagaya-ku, Tokyo, Japan, 158-8531
- Boehringer Ingelheim Investigational Site
-
Seto, Aichi, Japan, 489-8642
- Boehringer Ingelheim Investigational Site
-
Shibetsu, Hokkaido, Japan, 095-0014
- Boehringer Ingelheim Investigational Site
-
Shibuya-ku, Tokyo, Japan, 150-0013
- Boehringer Ingelheim Investigational Site
-
Shibuya-ku, Tokyo, Japan, 150-8935
- Boehringer Ingelheim Investigational Site
-
Shinagawa, Tokyo, Japan, 140-8522
- Boehringer Ingelheim Investigational Site
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Boehringer Ingelheim Investigational Site
-
Shinjyuku-ku, Tokyo, Japan, 162-8666
- Boehringer Ingelheim Investigational Site
-
Shiojiri, Nagano, Japan, 399-0702
- Boehringer Ingelheim Investigational Site
-
Sunagawa, Hokkaido, Japan, 073-0196
- Boehringer Ingelheim Investigational Site
-
Takamatsu, Kagawa, Japan, 760-0018
- Boehringer Ingelheim Investigational Site
-
Takarazuka, Hyogo, Japan, 665-0827
- Boehringer Ingelheim Investigational Site
-
Takasaki, Gunma, Japan, 370-0069
- Boehringer Ingelheim Investigational Site
-
Takatsuki, Osaka, Japan, 569-1096
- Boehringer Ingelheim Investigational Site
-
Tama, Tokyo, Japan, 206-0025
- Boehringer Ingelheim Investigational Site
-
Toride, Ibaraki, Japan, 302-0022
- Boehringer Ingelheim Investigational Site
-
Tosu, Saga, Japan, 841-0061
- Boehringer Ingelheim Investigational Site
-
Toyohashi, Aichi, Japan, 441-8021
- Boehringer Ingelheim Investigational Site
-
Toyohashi, Aichi, Japan, 441-8570
- Boehringer Ingelheim Investigational Site
-
Toyota, Aichi, Japan, 471-8513
- Boehringer Ingelheim Investigational Site
-
Tsuchiura, Ibaraki, Japan, 300-0047
- Boehringer Ingelheim Investigational Site
-
Tsuchiura,Ibaraki, Japan, 300-0053
- Boehringer Ingelheim Investigational Site
-
Tsukuba, Ibaragi, Japan, 305-0812
- Boehringer Ingelheim Investigational Site
-
Uji, Kyoto, Japan, 611-0013
- Boehringer Ingelheim Investigational Site
-
Ushiku, Ibaraki, Japan, 300-1296
- Boehringer Ingelheim Investigational Site
-
Uwajima, Ehime, Japan, 798-8510
- Boehringer Ingelheim Investigational Site
-
Yokohama, Kanagawa, Japan, 222-0033
- Boehringer Ingelheim Investigational Site
-
Yokohama, Kanagawa, Japan, 227-0046
- Boehringer Ingelheim Investigational Site
-
Yokohama, Kanagawa, Japan, 227-0062
- Boehringer Ingelheim Investigational Site
-
Yokohama, Kanagawa, Japan, 235-0045
- Boehringer Ingelheim Investigational Site
-
Yokohama, Kanagawa, Japan, 236-0016
- Boehringer Ingelheim Investigational Site
-
Yokohama, Kanagawa, Japan, 240-8585
- Boehringer Ingelheim Investigational Site
-
Yokohama, Kanagawa, Japan, 247-0006
- Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients who are able to visit the study site throughout the run-in period
- Aged 30 and 74 years
- Type II diabetes mellitus
- Patients with urinary albumin to creatinine ratios within the following ranges at 2 measuring points during the run-in period 1) the first-morning voided urine, iin the range of 100 to 300 mg/g Creatinine 2) < 100 mg/g Creatinine at either point of Visit 2 or 3, but in the range of 100 to 300 mg/g Creatinine at follow-up
- Serum creatinine level of < 1.5 mg/dL in male and < 1.3 mg/dL in female
- Normotensive or hypertensive patients
- Patients taking AT1 antagonists or ACE inhibitors at screening, but are able to stop those drugs during the study
- Patients who are able to provide written informed consent in accordance with the Good Clinical Practice (GCP) and other relevant laws such as the Pharmaceutical Affairs Law
Exclusion Criteria:
- Age of onset of type 2 diabetes is < 30 years
- Type I diabetes
- Urinary albumin to creatinine ratio of > 300 mg/g Creatinine
- HbA1c 9%
- Seated SBP 180 mmHg or DBP 110 mmHg
- Findings suggesting a renal disease other than diabetic nephropathy; such as post renal transplantation, history of non-diabetic renal disease, marked haematuria, complication of urinary tract infection
Cardiovascular diseases:
- Patients with unstable angina, myocardial infarction, CABG, PTCA within 6 months before
- CHF with NYHA III-IV
- TIA within 6 months
- Stroke within 6 months
- AV block (grade II-III) or AF
- Serious arrhythmia
- Known or suspected secondary HT
- History of angioedema during administration of ARB/ACE-i
- Hypersensitivity
- History of sudden exacerbation of renal function due to ARB/ACE-i
- Markedly poor bile secretion
- Hepatic dysfunction: SGPT (ALT) or SGOT (AST) 100 IU/L
- Serum potassium level < 3.5 mEq/L or 5.1 mEq/L
- Unable to discontinue ARB/ACE-i
- Require prolonged administration of any medications affecting blood pressure, except diuretics, or blockers, and CCB
- Untreated sodium depletion
Pre-menopausal females who meet any one of the following:
- Pregnant or possibly pregnant
- Breast-feeding
- Hope to be pregnant during the study period
- Even when a patient is confirmed not to meet the above criteria at the start of the study, a female patient who has the potential to be pregnant during the study is to undergo pregnancy tests. If the result turns positive, the study medication should be discontinued.
- Malignant tumour or other diseases requiring oral or injection immunosuppressants
- Non-compliance
- History of drug or alcohol abuse
- Participated in other clinical studies within 3 months
- Any other conditions investigators judged as ineligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Non-transition to overt nephropathy
|
Secondary Outcome Measures
Outcome Measure |
---|
Change in renal parameters Composite endpoint
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 502.413
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathies
-
NephroGenex, Inc.Medpace, Inc.; Collaborative Study Group (CSG)TerminatedDiabetic Nephropathy | Diabetic Kidney DiseaseUnited States, Australia, Bulgaria, France, Germany, Hong Kong, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain
-
University of MilanActive, not recruitingDiabetic Nephropathy Type 2Italy
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States